Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression

Lignende værker

• New therapy with ASC-J9(®) to suppress the prostatitis via altering the cytokine CCL2 signals
  af: Lin, Shin-Jen, et al.
  Udgivet: (2016)
• Anti-androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9(®) enhances BCG efficacy to better suppress bladder cancer progression
  af: Shang, Zhiqun, et al.
  Udgivet: (2015)
• ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
  af: Chi-Ping Huang, et al.
  Udgivet: (2019-06-01)
• ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
  af: Huang, Chi-Ping, et al.
  Udgivet: (2019)
• Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer
  af: Izumi, Kouji, et al.
  Udgivet: (2014)